Lindsay Bealor Greenleaf, head of Federal and State Policy at ADVI Health, talks with Managed Healthcare Executive about Robert F. Kennedy Jr., President Donald Trump’s HHS secretary nominee.
After the hearings in which Senators from the Finance Committee quizzed Robert F. Kennedy Jr., the HHS secretary nominee, but before this week’s committee vote, Lindsay Bealor Greenleaf, head of Federal and State Policy at ADVI Health, spoked with Managed Healthcare Executive about what Kennedy’s confirmation could mean for HHS, Medicare and Medicaid, and the Inflation Reduction Act.
Greenleaf said the despite Kennedy’s gaps in knowledge about Medicare and Medicaid and his controversial views about vaccine, he still has a good chance of being confirmed by the full Senate.
“Most Republicans would view [Kennedy] as being qualified, and his background and an attorney as fighting these issues that are so focused on healthcare, the way he has shaped this Make America healthy again movement. This is who President Trump wants to put in place for this position, so seems like his chances are pretty good of getting confirmed,” she said. “It would take a lot [for Republican senators] to want to go against the president.”
Regarding Medicare and Medicaid, Greenleaf suggested that Kennedy, if confirmed, would likely rely on people overseeing these programs, at least initially.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Medicaid Work Requirements Could Lead to Major Coverage Losses Across Expansion States in the U.S.
April 15th 2025The analysis from the Urban Institute breaks down projected coverage losses across the 40 Medicaid expansion states, where researchers based their estimates on previous work requirement rollouts in Arkansas and New Hampshire.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Analysis Finds Brukinsa May Provide Costs Savings Over Imbruvica in CLL
April 14th 2025In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.
Read More